You are using an old and unsupported browser. Upgrade to a modern browser for a better experience

Times are shown in your local time zone (GMT )
Arthramid Vet

Arthramid Vet

dual New Zealand and Australian companies
About Arthramid Vet
Arthramid® Vet 2.5% polyacrylamide hydrogel (PAAG) - The Future of Arthritis Treatment. Arthramid Vet is proven highly effective in treating non-infectious causes of joint lameness in horses, including both early and late stages of osteoarthritis (OA). After introduction to the joint, the gel becomes fully integrated into the synovium and joint capsule by a combination of cell migration and vessel ingrowth forming a thick, cushion-like membrane that increases the elasticity and tensile strength of the joint, reducing the pain and inflammation of synovitis and restoring long-lasting joint function. Arthramid Vet is the flagship product of Innovative Medical Solutions (IMS) Vet and has been developed for the Australasian, Asian and Middle East animal markets. The company is positioned as a key leader in researching, developing and promoting innovative products for the veterinary market created around a small but dedicated team of passionate people. We research and promote the best veterinary technologies from around the world for veterinarians in Australia, New Zealand, Hong Kong, Singapore, Japan, South East Asia and The Middle East.
Add to Favourites

Resources

Brochure outlining the product, mode of action, efficacy, case selection and administration.
Product summary and practical information for case selection and management.
De Clifford et al 2019 (JEVS) paper on Arthramid Vet treatment of 89 joints in 49 Australian racing Thoroughbreds. RESULTS: 43% were sound at Week 4, 67% sound at Week 12 and 65% sound at Week 24 with another 14% improved enough to return to work.
Detailed background of osteoarthritis, the product Arthramid Vet and how it can be used effectively in clinical practice to treat lameness.
#VetFest 2020
VetFest 2020
#VetFest 2020
Home
Streams